Coya Therapeutics Announces Publication of Preclinical Data Supporting COYA 303’s Immunomodulatory Effects

Coya Therapeutics Publishes Preclinical Findings for COYA 303 in Neuroinflammation Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on developing biologic therapies designed to enhance regulatory T-cell (Treg)…

Read MoreCoya Therapeutics Announces Publication of Preclinical Data Supporting COYA 303’s Immunomodulatory Effects

Alzheon Reports Positive ALZ-801 Biomarker and Clinical Outcomes in Early Alzheimer’s Disease

Alzheon Reports Biomarker Findings Supporting Potential Disease-Modifying Effects of Valiltramiprosate in Early Alzheimer’s Disease Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing investigational therapies and diagnostic assays for Alzheimer’s…

Read MoreAlzheon Reports Positive ALZ-801 Biomarker and Clinical Outcomes in Early Alzheimer’s Disease